Merck & Co's US withdrawal of antibiotic Recarbrio raises concerns on resistance efforts

Merck & Co's decision to withdraw the last-resort antibiotic combination Recarbrio from the US market has reignited concerns about the challenges in funding critical but infrequently used drugs. This move raises questions about the strategies for combating antibiotic resistance effectively.

Originally published by gnews